Ketamine administration in depressive disorders: a systematic review and meta-analysis. - Wikidata - awgldk - TriplyDB

Ketamine administration in depressive disorders: a systematic review and meta-analysis.

Ketamine administration in depressive disorders: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q38231235

about

Pharmacological interventions for self-harm in adults Interventions for self-harm in children and adolescents Kynurenine pathway metabolites and suicidality Pharmacological Approaches for Treatment-resistant Bipolar Disorder Remission From Behavioral Dysregulation in a Child With PTSD After Receiving Procedural Ketamine The role of inflammation in suicidal behaviour The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects Differential effects of rumination and distraction on ketamine induced modulation of resting state functional connectivity and reactivity of regions within the default-mode network.The neuroscience of depression: implications for assessment and intervention.Oral Ketamine in Treatment-Resistant Depression: A Clinical Effectiveness Case Series A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder.Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial Use of repeated intravenous ketamine therapy in treatment-resistant bipolar depression with suicidal behaviour: a case report from Spain.Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders.Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial.Glutamate NMDA receptor modulators for the treatment of depression: trials and tribulations.Suicide and suicidal behaviour Beyond serotonin: newer antidepressants in the future.Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.Study protocol for the randomised controlled trial: Ketamine augmentation of ECT to improve outcomes in depression (Ketamine-ECT study).Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.Ketamine for depression relapse prevention following electroconvulsive therapy: protocol for a randomised pilot trial (the KEEP-WELL trial).Increased PKC activity and altered GSK3β/NMDAR function drive behavior cycling in HINT1-deficient mice: bipolarity or opposing forces.Multistage drug effects of ketamine in the treatment of major depression.The promise of ketamine for treatment-resistant depression: current evidence and future directions.Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review.Ketamine modulates subgenual cingulate connectivity with the memory-related neural circuit-a mechanism of relevance to resistant depression?Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies.Ketamine for treatment-resistant depression: recent developments and clinical applications.KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.Suicidality and Activation of the Kynurenine Pathway of Tryptophan Metabolism.Is there a future for other glutamate receptor modulators in the pharmacotherapy of mood disorders?Can neurophysiologic measures serve as biomarkers for the efficacy of repetitive transcranial magnetic stimulation treatment of major depressive disorder?

P2860

Q24186543-0BD3542E-FE9A-4F06-93A6-BC0BD2E9A707 Q24187033-E74B5791-A72A-470F-AC52-18D1BD4BFC3B Q26773067-6B208D95-3E1B-415C-9662-95CE04C765A5 Q26783002-07E99527-C88B-451E-8178-6C325D268F2E Q26799619-EC1A83E6-A276-4949-A3C8-ADD82E19E5B7 Q26800426-B884B891-9986-499A-B50F-25FB16819938 Q28066714-9963232D-BFE6-459C-B1D9-A08AFF08AA09 Q28266846-8F6D468F-76A7-44E4-A20F-B60CEB8CC68C Q30357854-BF68090C-DF52-4648-80F6-DC5572D26EA4 Q30399725-4C0747D9-B8CD-43ED-9767-761FC06FEFE6 Q30491706-AAEF736C-E630-4690-8E9B-54A9B6FB52BF Q30987882-73C316AD-5EF5-490A-B926-BCD9126914AC Q33607667-1B67BACC-DA3C-4AEA-A052-EB7880E51585 Q33693374-E9134080-DA4D-4431-BD82-E2FF7CB4C29E Q33721019-49B2ECDF-49A6-4903-94F9-81EEE957C78A Q33747674-2DA20C81-5CF2-4171-9DD7-E14B4EB27451 Q34466310-DEFAD68E-6D88-4F25-8A49-1155001C0348 Q34494779-EB6B98EE-9C23-457A-A8E5-456DF5FE5A66 Q34557706-FE5B2603-0364-421E-8663-377EE7A54C16 Q35547495-3DDFBC8A-A3D7-45EB-8669-DDD41462D1F2 Q35816486-32CD2462-A6C1-458B-9F97-BD5038355C90 Q36176755-7CACD0CD-6ADC-4DA7-AE39-D74A6AED230F Q37197216-A6BD251D-DBA7-4B6F-8779-5359B6BA3ACD Q37424333-8AC54062-022D-447E-84EC-24DBC89613A7 Q37498103-2762EC10-1337-44F5-8C6F-DD479E95F24D Q37668134-C3DBCA84-3D87-41BE-9D6F-37C19C202726 Q38248776-A66134D8-E123-4365-8165-F805C962DDEE Q38343315-63E96632-FC12-48A9-930E-758820FFC600 Q38377259-B4657EA0-F53A-484A-A2A9-2FB0CFA3EB1D Q38476909-845C2AC1-1177-4F42-B978-F89CF6D1C537 Q38633125-ABA03467-C4D7-4136-B56C-1B8B280DDCC1 Q38647409-F086ECF0-C7C6-450F-B3ED-76BB4D0C06AC Q38787388-2EB52A04-4EA6-48E1-810A-78EC7BF276B6 Q38800172-E6F819E3-3B4F-45C5-B91A-7A07DC4667C1 Q38803371-2E00942B-CD22-4DF3-9629-A37EFBB57A7C Q38803429-28C868FD-82E0-4E7E-9EA5-4BFA66F5B43C Q38838637-FE750716-ED20-4D5D-B193-64D7B8CE6131 Q38843530-B2D53956-58A0-4E46-B54C-AB848A519B22 Q38860021-B05BA2A3-A4C9-4D5B-B909-BC6026F57395 Q38864824-41440A5C-903B-4BB2-A8FC-E8360D8F4184

P2860

Ketamine administration in depressive disorders: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q38231235

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Ketamine administration in depressive disorders: a systematic review and meta-analysis.

@en

type

label

Ketamine administration in depressive disorders: a systematic review and meta-analysis.

@en

prefLabel

Ketamine administration in depressive disorders: a systematic review and meta-analysis.

@en

P1433

Q38231235-3B5480D4-5E58-4ADE-9821-5A269F4D136E

P1476

Q38231235-83DAE6F3-82F8-4E27-B728-E05478286541

P2093

Q38231235-65922D67-C2EC-4047-AC1B-97B4475DC667

Q38231235-7B313B6A-9389-41DB-9E35-3CF83ACC94F3

Q38231235-7CA42CC4-6326-4001-9BA7-1AB2AC218AB0

Q38231235-7FF2134B-611E-4010-A985-87BBB67C16E1

Q38231235-80138EC6-47CC-4A76-93A7-BE0109E78484

Q38231235-8A87EDA1-9B7D-4B95-823C-505E18DE360C

Q38231235-AA99884D-8534-4B64-8017-F3D97B70A807

Q38231235-D6F09BC9-8F14-4CCC-959C-60484280D025

P2860

Q38231235-05A0BB29-E426-40F1-AEE6-71B7633A538D

Q38231235-0BD5E4FE-C630-421A-A00F-16E4E2E9DD01

Q38231235-43713B2E-2562-4560-8B4A-3F632CA0FF39

Q38231235-43E46928-FB62-4B33-BC6C-CF72723A0A8B

Q38231235-4C63E4F9-BD84-4D57-BCE3-1E5E35D3FABC

Q38231235-505B058A-4A2E-493C-A53D-4850A9D41DA9

Q38231235-541C2778-FB0D-4CCB-9174-0E2089C8D8F1

Q38231235-60086DDE-14E0-4309-8997-CB503CB2E665

Q38231235-658A9B5B-5F7B-4CAF-AFB2-B1143917306A

Q38231235-66F4C4C7-5B37-46CB-A58D-34BF3E9B0717

P2888

Q38231235-E41CA527-D222-41B0-9A43-2DE37E3B9428

P304

Q38231235-B081FE9C-A0F8-42E2-8F9D-B11E622A1494

P31

Q38231235-38CC378C-7D8A-4EA3-8D35-0988A388F581

Q38231235-950815fd-9bee-44ca-85c2-e298efe65585

P356

Q38231235-1105F2A3-591C-4556-895E-01F09E8F0CA9

P433

Q38231235-91C92511-1B5A-4E5D-9C53-6F5F19139660

P478

Q38231235-569AAEA6-077F-4A53-A0F8-2E79D9215931

P50

Q38231235-2A62AC20-7864-476A-9DCA-E99A894F6C9F

Q38231235-43C912D6-23FA-4BA0-8410-7A7D6C40A4F0

Q38231235-B56A84F0-8C76-49F7-B181-B6B1E054A01E

Q38231235-C93023E2-C5BD-46EA-934D-E83F2AD65F49

Q38231235-F06265AD-CD2C-4F98-9591-DA5FD8967810

P577

Q38231235-B7EE65AF-C337-4BDE-B80A-ADFAFDDBDC36

P5875

Q38231235-A9384B62-6312-4C1D-87FF-6B1433629676

P6179

Q38231235-4E0C919D-66F0-41B9-A0CE-5DE8E82566CA

Q38231235-93874127-926C-4AC0-9F9F-7BBC386DC70A

P698

Q38231235-C0BE292B-ACED-485D-ACEB-3353194562F9

P356

S00213-014-3664-5

P1433

Psychopharmacology

P1476

Ketamine administration in depressive disorders: a systematic review and meta-analysis.

@en

P2093

Alexandra Macgregor

http://www.w3.org/2001/XMLSchema#string

Anderson Loundou

http://www.w3.org/2001/XMLSchema#string

Corentin Rabu

http://www.w3.org/2001/XMLSchema#string

Laurent Boyer

http://www.w3.org/2001/XMLSchema#string

Marie Brittner

http://www.w3.org/2001/XMLSchema#string

Matthieu Roger

http://www.w3.org/2001/XMLSchema#string

Mocrane Abbar

http://www.w3.org/2001/XMLSchema#string

Philippe Courtet

http://www.w3.org/2001/XMLSchema#string

P2860

Grand challenges in global mental health

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

Measuring inconsistency in meta-analyses

Meta-analysis in clinical trials

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

Antidepressant effects of ketamine in depressed patients

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

Ketamine use: a review.

P2888

s00213-014-3664-5

P304

3663-3676

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00213-014-3664-5

http://www.w3.org/2001/XMLSchema#string

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

231

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Arthur Micoulaud-Franchi

Christophe Lançon

Raphaëlle Richieri

P577

2014-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264054674

http://www.w3.org/2001/XMLSchema#string

P6179

1008340109

http://www.w3.org/2001/XMLSchema#string

P698

25038867

http://www.w3.org/2001/XMLSchema#string